The FDA accepted uniQure’s AMT-130 application for Huntington’s disease, granted priority review, and set a May 1, 2027, target decision date while approval remains uncertain.
Huntington’s Gene Therapy AMT-130 Gets FDA Priority Review and a May 2027 Decision Date, Advisory Panel Planned
by | Nov 4, 2026 | Uncategorized | 0 comments
Recent Comments